SMC accepts Cabometyx/Opdivo combo for advanced kidney cancer patients

Pharma Times

13 October 2021 - The SMC has recommended Cabometyx (cabozantinib) plus Opdivo (nivolumab) for use by via NHS Scotland for the first-line treatment of advanced renal cell carcinoma in adults.

In a Phase 3 trial, the risk of death for advanced renal cell carcinoma patients was decreased by 34% with the Cabometyx plus Opdivo combination compared to currently availably therapy sunitinib.

Read Pharma Times article

Michael Wonder

Posted by:

Michael Wonder